Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs Insulin Glargine in Japanese T2DM Patients
NCT01584232Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Primary completion
- Jul 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 weeks. Started Apr 2012; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01584232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01584232.